Medicine
Showing 1-3 of 3 Results
-
Alexander Isaac Salter
Postdoctoral Medical Fellow, Oncology
Fellow in Medicine - Med/HematologyBioI am a clinical fellow in medical oncology at Stanford University whose long-term goal is to become a translational physician-scientist who develops curative cellular immunotherapies for solid tumors. As a graduate student, I conducted the first comprehensive signaling analyses of therapeutically engineered T cells, demonstrating that signal strength, rather than quality, is a key determinant of T cell function and fate. These findings helped inform the design of next-generation cellular immunotherapies, some of which are now in clinical trials. I also co-led a collaboration with Dr. David Baker’s laboratory at the University of Washington to engineer synthetic protein “logic gates” enabling combinatorial antigen recognition with high precision, offering a potential path to more safely target solid tumors. My doctoral research resulted in 16 publications, including four prominent first-, co-first-, or second-author papers in high-impact journals, several reviews and textbook chapters, and recognition on the Forbes 30 Under 30 List.
At Stanford, I focus on translating cellular therapies for thoracic and genitourinary malignancies. Under the mentorship of Drs. Crystal Mackall and Allison Betof Warner, I am developing CAR T cells for lung cancer in non- and never-smokers and serve as a sub-investigator on an upcoming first-in-human phase 1 trial of drug-regulatable CAR T cells for adults with advanced solid tumors. -
Takeshi Sugio
Postdoctoral Scholar, Oncology
BioI am a physician-scientist and hematologist focused on clinical translation of T-cell biology. I received my MD from Kyushu University, and subsequently completed Residency Training at Toranomon Hospital, the largest transplant center in Japan. I continued my Hematology training at Kyushu University, where I qualified as a Board-certified specialist (2017) and supervisory hematologist (2021) by the Japanese Society of Hematology. For my PhD (2014-19), I studied expression profiles and histologic features of TCLs. I discovered distinct TCL clinical groups identified by infiltrating immune cell patterns in the microenvironment. Based on my dissertation work (Sugio, et al 2018 Blood Advances), I planned and conducted a Phase II trial of PD1 inhibition for relapsed/refractory TCL (UMIN000034499). I joined the Alizadeh lab at Stanford in 2021, where I am developing tools to analyze immune status using liquid biopsies.
